Pair page
Pal-GHK with Syn-Coll
Mechanism-tag overlap and published literature for Pal-GHK and Syn-Coll, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Pal-GHK unique
palmitoylated-copper-peptide-analog
Shared
cosmetic-peptide
Syn-Coll unique
tgf-mimetic-collagen-signal
Quick facts
Pal-GHK
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient
WADAN/A (topical cosmetic)
Syn-Coll
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient (not drug)
WADAN/A (topical cosmetic)
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2005 | Pal-GHK | Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005;27(3):155-160. doi:10.1111/j.1467-2494.2005.00261.x. PMID: 18492182. (Found… PMID 18492182 | human trial |
| 1998 | Pal-GHK | Abdulghani AA, Sherr A, Shirin S, Solodkina G, Tapia EM, Wolf B, Gottlieb AB. Effects of topical creams containing vitamin C, a copper-binding peptide cream, and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastruct… | human pilot |
| 1988 | Pal-GHK | Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID: 3138181. (Th… PMID 3138181 | preclinical, in vitro |
| 2018 | Pal-GHK | Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520; PMC6073405. (2018 gene-expression-based review using Broad… PMID 29986520 | mechanism / discovery |
| 2017 | Pal-GHK | Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences. 2017;7(2):20. doi:10.3390/brainsci7020020. PMID: 28241430. (Extension of GHK transcriptomic effects; rele… PMID 28241430 | mechanism / discovery |
| 2018 | Pal-GHK | Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029. (Contemporary MDPI Cosmetics review of copper-peptide skin biology applicable to the Pal-GHK-in-situ-GHK-Cu formation hypothesis.) | review |
| 2015 | Pal-GHK | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730; PMC4508379. (Comprehensive review of GHK's multi-pathway s… PMID 26236730 | review |
| 2008 | Pal-GHK | Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225. (Foundational review of the parent tripeptide GHK, its tissue-remodeling biology, and the copper-coor… PMID 18644225 | review |
| 2005 | Pal-GHK | Finkley MB, Appa Y, Bhandarkar S. Copper peptide and skin. Cosmeceuticals and Active Cosmetics: Drugs vs. Cosmetics. Marcel Dekker, New York; 2005:549–563. (Classical cosmetic-dermatology chapter summarizing GHK-Cu-containing facial cream clinical data — the cream data most ofte… | review |
| 2003 | Pal-GHK | Sederma (Croda International). Matrixyl 3000 technical dossier and product information sheets. Sederma, Le Perray-en-Yvelines, France. 2003–2024. (Manufacturer's technical documentation for the Pal-GHK + Pal-GQPR combination active — the primary source for recommended use levels… | industry documentation |
| 2002 | Pal-GHK | Mas-Chamberlin C, Lintner K, Basset L, Adhoute H, Revuz J. Relevance of antiwrinkle treatment of a peptide: 4 months clinical double blind study vs excipient. Annales de Dermatologie et de Vénéréologie. 2002;129(1S):456. Proceedings, 20th World Congress of Dermatology, Paris. (E… | industry documentation |
| 2000 | Pal-GHK | Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International Journal of Cosmetic Science. 2000;22(3):207-218. doi:10.1046/j.1467-2494.2000.00010.x. (Sederma researcher review of the palmitoyl-peptide lipi… | industry documentation |
| 1998 | Syn-Coll | Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998;93(7):1159-1170. doi:10.1016/s0092-8674(00)81460-9. PMID: 9657149. (Genetic demonstration in TSP-1-null mice th… PMID 9657149 | preclinical, in vivo |
| 1987 | Syn-Coll | Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 1987;247(3):597-604. doi:10.1042/bj2470597. PMI… PMID 3501287 | preclinical, in vitro |
| 2004 | Syn-Coll | Young GD, Murphy-Ullrich JE. Molecular interactions that confer latency to transforming growth factor-beta. J Biol Chem. 2004;279(36):38032-38039. doi:10.1074/jbc.M405658200. PMID: 15208302. (Biochemical characterization of the LAP "latency lasso" that TSP-1 KRFK disrupts.) PMID 15208302 | mechanism / discovery |
| 1992 | Syn-Coll | Murphy-Ullrich JE, Schultz-Cherry S, Höök M. Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell. 1992;3(2):181-188. doi:10.1091/mbc.3.2.181. (Original biochemical characterization of the TSP-1 / TGF-β complex.) | mechanism / discovery |
| 1986 | Syn-Coll | Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261(9):4337-4345. PMID: 3456347. (Early demonstration of TGF-β–driven matrix gene expression; co-… PMID 3456347 | mechanism / discovery |
| 2018 | Syn-Coll | Murphy-Ullrich JE, Suto MJ. Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease. Matrix Biol. 2018;68-69:28-43. doi:10.1016/j.matbio.2017.12.009. (Comprehensive modern review of TSP-1 / TGF-β targeting for disease; PMC6015530.) | review |
| 2007 | Syn-Coll | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. doi:10.1111/j.1529-8019.2007.00148.x. PMID: 18045359. (The most widely cited dermatology review of cosmeceutical peptides; positions palmitoyl tripeptide-5 within the signal-peptide class.) PMID 18045359 | review |
| 2000 | Syn-Coll | Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11(1-2):59-69. doi:10.1016/s1359-6101(99)00029-5. PMID: 10708953. (Definitive mechanistic review of TSP-1-dependent TGF-β activation.) PMID 10708953 | review |
| — | Syn-Coll | Cosmetic Ingredient Review Expert Panel. Safety Assessment of Palmitoyl Oligopeptides and Palmitoyl Polypeptides as Used in Cosmetics. Int J Toxicol. CIR Final Report (periodic updates). (Regulatory safety review of the palmitoyl-peptide class, including palmitoyl tripeptide-5.) | review |
| 2009 | Syn-Coll | Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Dermatol Clin. 2009;27(4):401-416, v. doi:10.1016/j.det.2009.05.006. PMID: 19850190. (Dermatology practice-level overview of cosmeceutical peptide use, including TGF-β–mimetic tripeptides.) PMID 19850190 | research article |
| 2004 | Syn-Coll | Young GD, Murphy-Ullrich JE. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem. 2004;279(46):47633-47642. doi:10.1074/jbc.M404918200. PMID: 15347654. (Identification of the WxxW "do… PMID 15347654 | research article |
| 1999 | Syn-Coll | Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem. 1999;274(19):13586-13593. doi:10.1074/… PMID 10224129 | research article |
Related pair pages
More research context
Frequently asked
Have Pal-GHK and Syn-Coll been studied together?
No co-administration studies between Pal-GHK and Syn-Coll are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Pal-GHK and Syn-Coll share?
Pal-GHK and Syn-Coll share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Pal-GHK and Syn-Coll?
Pal-GHK: Cosmetic ingredient. Syn-Coll: Cosmetic ingredient (not drug). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Pal-GHK and Syn-Coll?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Pal-GHK profile and the Syn-Coll profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026